Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
Study sponsor: Cardiff Oncology
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-12-09Actual
Enrollment · participants23Actual
Source updated2025-01-10Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.